RxDoctor Payments Data

Lisa Forehand, MD

Internal Medicine · Hamburg, NYNPI 1538127113

Payments from drug & device makers

$1,258in general payments, 2019–2025

Across 70 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$166
  • GSK$165
  • Novo Nordisk$141
  • Abbott$133
  • Lilly USA, LLC$124
  • AbbVie$56
  • plus $473 from 18 others

What the payments were for

  • Food & beverage$1,258100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,258 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$150,922
Medicare patients
315
Services billed
2,032

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide80$90,685
EliquisApixaban73$66,232
JardianceEmpagliflozin64$58,471
TrulicityDulaglutide51$49,925
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$33,182
OzempicSemaglutide31$32,821
JanuviaSitagliptin Phosphate25$27,220
RybelsusSemaglutide17$26,519
Tresiba Flextouch U-200Insulin Degludec33$22,182
LinzessLinaclotide22$14,713
Tresiba Flextouch U-100Insulin Degludec20$8,235
Repatha SureclickEvolocumab13$6,941
Levothyroxine Sodium371$6,267
Rosuvastatin Calcium293$5,457
Metoprolol Succinate231$5,362

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$124$140,610131 claims
Novo NordiskOzempic, Rybelsus$141$59,34148 claims
Boehringer IngelheimJardiance$30$58,47164 claims
GSKTrelegy Ellipta$165$33,18240 claims
MerckJanuvia, Dulera$32$31,11137 claims
AbbVieLinzess, Synthroid$56$16,21446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →